Neuronetics director buys $41.7k in company stock

Neuronetics , Inc. (NASDAQ:STIM) Director Robert Cascella has recently increased his stake in the company with the purchase of shares valued at approximately $41,660. The transactions, filed with the Securities and Exchange Commission, show Cascella acquiring shares at prices ranging from $1.06 to $1.14.

On August 16, 2024, Cascella bought 35,000 shares at $1.06 each, and on August 19, he purchased an additional 4,000 shares at $1.14 each. Following these transactions, Cascella's total ownership in Neuronetics stands at 353,098 shares.

Neuronetics is known for its innovative approach in the medical device sector, focusing on surgical and medical instruments and apparatus. The company's commitment to developing advanced therapies for neurological health issues has positioned it as a notable player in the industry.

Investors often keep an eye on insider transactions as they can provide insights into the executives' confidence in the company's future performance. Cascella's recent stock purchases might be interpreted as a positive signal regarding Neuronetics' outlook.

The company, with headquarters in Malvern, Pennsylvania, has been striving to expand its market reach and continues to invest in research and development to drive future growth.

As a director of Neuronetics, Cascella's involvement in the company's strategic decisions and his recent investment further align his interests with those of the shareholders. Investors will likely watch for any subsequent moves by company insiders for indications of Neuronetics' trajectory in the competitive medical device market.

In other recent news, Neuronetics, a medical technology company, reported a revenue of $16.5 million in the second quarter, falling short of expectations due to altered purchasing patterns influenced by the Change Health cyberattack earlier in the year. Despite this, the company observed an 18% growth in the utilization of local consumables, indicating robust demand for its treatments. Analysts at William Blair adjusted their stock rating from Outperform to Market Perform, recognizing the company's solid treatment demand but also acknowledging the financial challenges it faced.

Neuronetics is now focusing on its impending merger with Greenbrook TMS, which is expected to generate revenue and cost synergies, pushing the company towards sustained profitability from 2025. Analysts at Canaccord Genuity have adjusted their price target for Neuronetics shares while maintaining a Buy rating.

The company is also investing in its Better Me Guarantee Program and launching a television advertising campaign in Tampa Bay, Florida, aiming to increase therapy awareness. These recent developments are part of Neuronetics' strategic steps to navigate current challenges, with the goal of achieving positive cash flow in 2025.

InvestingPro Insights

In light of Director Robert Cascella's recent share purchases in Neuronetics, Inc. (NASDAQ:STIM), current and prospective investors may find additional context from InvestingPro data and insights valuable. According to InvestingPro, Neuronetics has a market capitalization of approximately $30.72 million, reflecting the company's size within the medical device sector. Despite the challenges, the firm has managed to maintain a gross profit margin of 75.91% over the last twelve months as of Q2 2024, which suggests that it is effective at controlling the cost of goods sold relative to its sales.

However, Neuronetics has been facing some financial headwinds. The company's price-to-earnings (P/E) ratio stands at -0.99, indicating that it has not been profitable over the last twelve months as of Q2 2024. This aligns with an InvestingPro Tip that analysts do not anticipate the company will be profitable this year. Moreover, the company is experiencing a negative return on assets of -32.93%, which raises questions about its asset efficiency.

InvestingPro also highlights that Neuronetics has been quickly burning through cash, which could be a concern for investors looking for financial stability. However, on the positive side, the company's liquid assets exceed its short-term obligations, suggesting that it has the liquidity to meet its current liabilities.

For those interested in the volatility and potential growth of Neuronetics' stock, another InvestingPro Tip notes that the stock has seen a significant return over the last week, with a total price return of 50.34%. This could be interpreted as a short-term bullish signal, although the stock has fared poorly over the last month with a price total return of -41.82%.

For additional insights, there are 12 more InvestingPro Tips available for Neuronetics, which can be found at https://www.investing.com/pro/STIM. These tips may provide further guidance for investors considering this company within their portfolio.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.